RT Journal Article
SR Electronic
T1 Risk factors for severe outcomes of COVID-19: a rapid review
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.08.27.20183434
DO 10.1101/2020.08.27.20183434
A1 Wingert, Aireen
A1 Pillay, Jennifer
A1 Gates, Michelle
A1 Guitard, Samantha
A1 Rahman, Sholeh
A1 Beck, Andrew
A1 Vandermeer, Ben
A1 Hartling, Lisa
YR 2020
UL http://medrxiv.org/content/early/2020/09/01/2020.08.27.20183434.abstract
AB Background Identification of high-risk groups is needed to inform COVID-19 vaccine prioritization strategies in Canada. A rapid review was conducted to determine the magnitude of association between potential risk factors and risk of severe outcomes of COVID-19.Methods Methods, inclusion criteria, and outcomes were prespecified in a protocol that is publicly available. Ovid MEDLINE(R) ALL, Epistemonikos COVID-19 in L·OVE Platform, and McMaster COVID-19 Evidence Alerts, and select websites were searched to 15 June 2020. Studies needed to be conducted in Organisation for Economic Co-operation and Development countries and have used multivariate analyses to adjust for potential confounders. After piloting, screening, data extraction, and quality appraisal were all performed by a single reviewer. Authors collaborated to synthesize the findings narratively and appraise the certainty of the evidence for each risk factor-outcome association.Results Of 3,740 unique records identified, 34 were included in the review. The studies included median 596 (range 44 to 418,794) participants with a mean age between 42 and 84 years. Half of the studies (17/34) were conducted in the United States and 19/34 (56%) were rated as good quality. There was low or moderate certainty evidence for a large (≥2-fold) association with increased risk of hospitalization in people having confirmed COVID-19, for the following risk factors: obesity class III, heart failure, diabetes, chronic kidney disease, dementia, age over 45 years (vs. younger), male gender, Black race/ethnicity (vs. non-Hispanic white), homelessness, and low income (vs. above average). Age over 60 and 70 years may be associated with large increases in the rate of mechanical ventilation and severe disease, respectively. For mortality, a large association with increased risk may exist for liver disease, Bangladeshi ethnicity (vs. British white), age over 45 years (vs. <45 years), age over 80 years (vs. 65-69 years), and male gender in those 20-64 years (but not older). Associations with hospitalization and mortality may be very large (≥5-fold increased risk) for those aged over 60 years.Conclusion Among other factors, increasing age (especially >60 years) appears to be the most important risk factor for severe outcomes among those with COVID-19. There is a need for high quality primary research (accounting for multiple confounders) to better understand the level of risk that might be associated with immigration or refugee status, religion or belief system, social capital, substance use disorders, pregnancy, Indigenous identity, living with a disability, and differing levels of risk among children.PROSPERO registration CRD42020198001What is already knownThe novel nature of COVID-19 means that in many countries there are currently no pre-determined priority groups for the receipt of the eventual COVID-19 vaccine(s).Primary research is rapidly emerging, but consensus on who might be at increased risk of severe outcomes from COVID-19 has not been established.What this study addsThis rapid review shows that advancing age (>45 years and especially >60 years) may be the most important risk factor for hospitalization and mortality from COVID-19.Other important risk factors for severe disease identified by this review include several pre-existing chronic conditions (class III obesity, heart failure, diabetes, chronic kidney disease, liver disease, dementia), male gender, Black race/ethnicity (vs. non-Hispanic white), Bangladeshi ethnicity (vs. British white), low income (vs. high), and homelessness.Competing Interest StatementCompeting interests declaration: All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: grants from the National Advisory Committee for Immunization during the conduct of the study; no other relationships or activities that could appear to have influenced the submitted work. LH is supported by a Canada Research Chair in Knowledge Synthesis and Translation.Clinical TrialPROSPERO registration: CRD42020198001Clinical Protocols https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=198001 Funding StatementAll authors declare grants from Canada's National Advisory Committee for Immunization (NACI) during the conduct of the study. The NACI High Consequence Infectious Disease Vaccine Working Group was consulted to develop and refine the scope of the review (i.e., priority population(s), risk condition(s)/factor(s), and outcomes of interest), but was not involved in the conduct of the review. The working group was not involved in selection of studies nor the synthesis of findings.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Not applicable. This work was conducted using published data, and therefore, ethics approval and patient consent was not required.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData sharing statement: All data used in this review are available within the manuscript and accompanying supplemental files.Data sharing statement: All data used in this review are available within the manuscript and accompanying supplemental files.